AbbVie (ABBV) Stock Forecast & Price Target

Compare

23,672 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABBV Analyst Ratings

Moderate Buy

15 Buy

7 Hold

0 Sell

Based on 22 analysts giving stock ratings to

AbbVie

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABBV Stock 12 Month Forecast

Average Price Target

$253.47

▲(15.38% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $253.47 with a high forecast of $299.00 and a low forecast of $223.00. The average price target represents a 15.38% change from the last price of $219.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"181":"$181","300":"$300","210.75":"$210.8","240.5":"$240.5","270.25":"$270.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":299,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$299.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":253.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$253.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":223,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$223.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[181,210.75,240.5,270.25,300],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,234.26,239.23999999999998,244.22,249.2,254.18,259.15999999999997,264.14,269.12,274.1,279.08,284.06,289.03999999999996,294.02,{"y":299,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,234.26,235.7376923076923,237.2153846153846,238.69307692307692,240.17076923076922,241.64846153846153,243.12615384615384,244.60384615384615,246.08153846153846,247.55923076923077,249.03692307692307,250.51461538461538,251.9923076923077,{"y":253.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,234.26,233.39384615384614,232.5276923076923,231.66153846153844,230.79538461538462,229.92923076923077,229.06307692307692,228.19692307692307,227.33076923076922,226.46461538461537,225.59846153846155,224.7323076923077,223.86615384615385,{"y":223,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":202.245,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.575,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.793,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.592,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.522,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.275,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207.226,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240.694,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":216.299,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.313,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.666,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.64,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":234.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$299.00

Average Price Target$253.47

Lowest Price Target$223.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mohit Bansal

Wells Fargo

$260

Buy

18.35%

Upside

Assigned

03/12/26

Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Relay Therapeutics (RLAY)

Luisa Hector

Berenberg Bank

$275

Buy

25.18%

Upside

Reiterated

03/12/26

AbbVie (ABBV) Receives a Buy from Berenberg Bank

Evan Seigerman

BMO Capital

$258

Buy

17.44%

Upside

Reiterated

03/11/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Pliant Therapeutics (NASDAQ: PLRX) and Opus Genetics (NASDAQ: IRD)

Geoff Meacham

Citi

$230

Hold

4.70%

Upside

Reiterated

03/10/26

Neutral Hold on AbbVie as Early Cardiometabolic Pipeline Shows Promise but Trails Leading Competitors

Louise Chen

Scotiabank

$280

Buy

27.46%

Upside

Reiterated

03/10/26

Scotiabank Reaffirms Their Buy Rating on AbbVie (ABBV)

Matt Phipps

William Blair

―

Buy

―

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Delcath Systems (NASDAQ: DCTH)

Chris Schott

J.P. Morgan

$260

Buy

18.35%

Upside

Reiterated

03/05/26

J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)

Terence Flynn

Morgan Stanley

$269→$270

Buy

22.91%

Upside

Reiterated

03/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Nico Chen

DBS

$230

Hold

4.70%

Upside

Reiterated

02/25/26

DBS Sticks to Their Hold Rating for AbbVie (ABBV)

Trung Huynh

RBC Capital

$260

Buy

18.35%

Upside

Initiated

02/24/26

AbbVie initiated with an Outperform at RBC CapitalAbbVie initiated with an Outperform at RBC Capital

Emily Field

Barclays

$275

Buy

25.18%

Upside

Initiated

02/19/26

AbbVie initiated with an Overweight at BarclaysAbbVie initiated with an Overweight at Barclays

David Amsellem

Piper Sandler

$289→$299

Buy

36.11%

Upside

Reiterated

02/18/26

AbbVie price target raised to $299 from $289 at Piper SandlerAbbVie price target raised to $299 from $289 at Piper Sandler

Courtney Breen

Bernstein

$225

Hold

2.42%

Upside

Reiterated

02/06/26

Balanced Risk-Reward and Fading Upside Visibility Keep AbbVie at Market-Perform (Hold) with $225 Target

Jason Gerberry

Bank of America Securities

$233→$226

Hold

2.88%

Upside

Reiterated

02/05/26

Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV)

Michael Yee

UBS

$240→$230

Hold

4.70%

Upside

Reiterated

02/05/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), 10x Genomics (NASDAQ: TXG) and Oruka Therapeutics (NASDAQ: ORKA)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mohit Bansal

Wells Fargo

$260

Buy

18.35%

Upside

Assigned

03/12/26

Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Relay Therapeutics (RLAY)

Luisa Hector

Berenberg Bank

$275

Buy

25.18%

Upside

Reiterated

03/12/26

AbbVie (ABBV) Receives a Buy from Berenberg Bank

Evan Seigerman

BMO Capital

$258

Buy

17.44%

Upside

Reiterated

03/11/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Pliant Therapeutics (NASDAQ: PLRX) and Opus Genetics (NASDAQ: IRD)

Geoff Meacham

Citi

$230

Hold

4.70%

Upside

Reiterated

03/10/26

Neutral Hold on AbbVie as Early Cardiometabolic Pipeline Shows Promise but Trails Leading Competitors

Louise Chen

Scotiabank

$280

Buy

27.46%

Upside

Reiterated

03/10/26

Scotiabank Reaffirms Their Buy Rating on AbbVie (ABBV)

Matt Phipps

William Blair

―

Buy

―

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Delcath Systems (NASDAQ: DCTH)

Chris Schott

J.P. Morgan

$260

Buy

18.35%

Upside

Reiterated

03/05/26

J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)

Terence Flynn

Morgan Stanley

$269→$270

Buy

22.91%

Upside

Reiterated

03/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Nico Chen

DBS

$230

Hold

4.70%

Upside

Reiterated

02/25/26

DBS Sticks to Their Hold Rating for AbbVie (ABBV)

Trung Huynh

RBC Capital

$260

Buy

18.35%

Upside

Initiated

02/24/26

AbbVie initiated with an Outperform at RBC CapitalAbbVie initiated with an Outperform at RBC Capital

Emily Field

Barclays

$275

Buy

25.18%

Upside

Initiated

02/19/26

AbbVie initiated with an Overweight at BarclaysAbbVie initiated with an Overweight at Barclays

David Amsellem

Piper Sandler

$289→$299

Buy

36.11%

Upside

Reiterated

02/18/26

AbbVie price target raised to $299 from $289 at Piper SandlerAbbVie price target raised to $299 from $289 at Piper Sandler

Courtney Breen

Bernstein

$225

Hold

2.42%

Upside

Reiterated

02/06/26

Balanced Risk-Reward and Fading Upside Visibility Keep AbbVie at Market-Perform (Hold) with $225 Target

Jason Gerberry

Bank of America Securities

$233→$226

Hold

2.88%

Upside

Reiterated

02/05/26

Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV)

Michael Yee

UBS

$240→$230

Hold

4.70%

Upside

Reiterated

02/05/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), 10x Genomics (NASDAQ: TXG) and Oruka Therapeutics (NASDAQ: ORKA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

3 Months

xxx

Success Rate

20/27 ratings generated profit

Average Return

+7.11%

assigned a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 74.07% of your transactions generating a profit, with an average return of +7.11% per trade.

1 Year

Evan SeigermanBMO Capital

Success Rate

19/19 ratings generated profit

Average Return

+19.72%

reiterated a buy rating 4 days ago

Copying Evan Seigerman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +19.72% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+36.44%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +36.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABBV Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABBV has received 31 Buy Ratings, 22 Hold Ratings, and 0 Sell Ratings. ABBV average Analyst price target in the past 3 months is 253.47.

Each month's total comprises the sum of three months' worth of ratings.

ABBV Financial Forecast

ABBV Earnings Forecast

Next quarter’s earnings estimate for ABBV is $3.02 with a range of $2.97 to $3.17. The previous quarter’s EPS was $2.71. ABBV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.

ABBV Sales Forecast

Next quarter’s sales forecast for ABBV is $14.72B with a range of $14.56B to $14.85B. The previous quarter’s sales results were $16.62B. ABBV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.

ABBV Stock Forecast FAQ

What is ABBV’s average 12-month price target, according to analysts?

Based on analyst ratings, AbbVie’s 12-month average price target is 253.47.

What is ABBV’s upside potential, based on the analysts’ average price target?

AbbVie has 15.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABBV a Buy, Sell or Hold?

AbbVie has a consensus rating of Moderate Buy which is based on 15 buy ratings, 7 hold ratings and 0 sell ratings.

What is AbbVie’s price target?

The average price target for AbbVie is 253.47. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $299.00 ,the lowest forecast is $223.00. The average price target represents 15.38% Increase from the current price of $219.68.

What do analysts say about AbbVie?

AbbVie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of ABBV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

AbbVie (ABBV) Stock Forecast & Price Target

ABBV Analyst Ratings

ABBV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbbVie

ABBV Analyst Recommendation Trends

ABBV Financial Forecast

ABBV Earnings Forecast

ABBV Sales Forecast

ABBV Stock Forecast FAQ

Detailed List of Analyst Forecasts